These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 25394503)

  • 1. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
    Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
    Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
    Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
    Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.
    Wolchok JD; Yuan J; Houghton AN; Gallardo HF; Rasalan TS; Wang J; Zhang Y; Ranganathan R; Chapman PB; Krown SE; Livingston PO; Heywood M; Riviere I; Panageas KS; Terzulli SL; Perales MA
    Mol Ther; 2007 Nov; 15(11):2044-50. PubMed ID: 17726460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic DNA vaccine targeting Foxp3
    Namdar A; Mirzaei R; Memarnejadian A; Boghosian R; Samadi M; Mirzaei HR; Farajifard H; Zavar M; Azadmanesh K; Elahi S; Noorbakhsh F; Rezaei A; Hadjati J
    Cancer Immunol Immunother; 2018 Mar; 67(3):367-379. PubMed ID: 29124314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
    Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA
    Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against HPV-16-Associated Tumors Requires the Activation of CD8+ Effector Memory T Cells and the Control of Myeloid-Derived Suppressor Cells.
    Diniz MO; Sales NS; Silva JR; Ferreira LC
    Mol Cancer Ther; 2016 Aug; 15(8):1920-30. PubMed ID: 27222537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
    J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
    Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
    Sanders KL; Fox BA; Bzik DJ
    Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
    Bol KF; Aarntzen EH; Pots JM; Olde Nordkamp MA; van de Rakt MW; Scharenborg NM; de Boer AJ; van Oorschot TG; Croockewit SA; Blokx WA; Oyen WJ; Boerman OC; Mus RD; van Rossum MM; van der Graaf CA; Punt CJ; Adema GJ; Figdor CG; de Vries IJ; Schreibelt G
    Cancer Immunol Immunother; 2016 Mar; 65(3):327-39. PubMed ID: 26861670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
    Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
    Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
    Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
    Lesokhin AM; Hohl TM; Kitano S; Cortez C; Hirschhorn-Cymerman D; Avogadri F; Rizzuto GA; Lazarus JJ; Pamer EG; Houghton AN; Merghoub T; Wolchok JD
    Cancer Res; 2012 Feb; 72(4):876-86. PubMed ID: 22174368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.
    Tanaka M; Kaneda Y; Fujii S; Yamano T; Hashimoto K; Huang SK; Hoon DS
    Mol Ther; 2002 Mar; 5(3):291-9. PubMed ID: 11863419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
    Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments.
    Blidner AG; Salatino M; Mascanfroni ID; Diament MJ; Bal de Kier Joffé E; Jasnis MA; Klein SM; Rabinovich GA
    J Immunol; 2015 Apr; 194(7):3452-62. PubMed ID: 25740944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.